Immatics (IMTX) Reports Q3 Loss, Tops Revenue Estimates
Immatics (IMTX) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.35 per share a year ago.
Immatics (IMTX) Expected to Beat Earnings Estimates: Should You Buy?
Immatics (IMTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Immatics: A Promising TCR Pipeline
Immatics is an early-stage biotech focused on cell-based immunotherapies for solid cancers. Their ACTEngine pipeline shows promise, particularly IMA203/IMA203CD8 targeting the PRAME antigen. Valuation estimates suggest a potential stock price of ~$19.26 based on conservative revenue assumptions.
Why Is Cancer-Focused Immatics Stock Trading Lower On Thursday?
On Thursday, Immatics N.V. IMTX stock is trading lower after the company commenced an underwritten public offering of $150 million.
Immatics (IMTX) Reports Q2 Loss, Tops Revenue Estimates
Immatics (IMTX) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.35 per share a year ago.
Wall Street Analysts Predict a 54.95% Upside in Immatics (IMTX): Here's What You Should Know
The consensus price target hints at a 55% upside potential for Immatics (IMTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Here's Why 'Trend' Investors Would Love Betting on Immatics (IMTX)
If you are looking for stocks that are well positioned to maintain their recent uptrend, Immatics (IMTX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
